Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment

Thomas McFarlane\textsuperscript{1,2}, Noor Rehman\textsuperscript{1}, Katie Wang\textsuperscript{1}, Jenny Lee\textsuperscript{1}, Caitlin Carter\textsuperscript{1}

\textsuperscript{1}School of Pharmacy, Faculty of Science, University of Waterloo, Kitchener, ON, Canada; \textsuperscript{2}Odette Cancer Centre, Sunnybrook Health Sciences, Toronto, ON, Canada

Contributions: (I) Conception and design: T McFarlane, C Carter; (II) Administrative support: None; (III) Provision of study materials or patients: C Carter; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: T McFarlane, N Rehman, K Wang, J Lee; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Thomas McFarlane. Sunnybrook Health Sciences, 2075 Bayview Avenue, Toronto, ON M4N 3M5, USA.
Email: tom.mcfarlane@sunnybrook.ca.

Abstract: The world of oncology treatment is rapidly changing, and with the investigation into and utilization of molecular signaling pathways for cancer treatment, many new targeted small-molecule oral agents have been introduced as therapies, with more new drugs appearing every year. These agents, while generally considered less toxic overall than traditional chemotherapy, are not without adverse effects. The authors undertook an extensive literature search to determine the incidence, severity, and management strategies for small-molecule oral targeted agents approved by the FDA between 2013 and 2018. Dermatologic adverse effects are among the most frequently seen with many of these targeted therapies, and may include rashes, palmar-plantar dysesthesia, alopecia, secondary skin malignancies, and hair and nail changes. Rarely, more severe cutaneous toxicities are seen, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis. In many cases, there is no specific management strategy suggested in the literature for these toxicities, but frequent monitoring of the skin, prophylactic management of palmar-plantar dysesthesia, use of corticosteroids and/or antihistamines, and intervention with dose interruption are suggested depending on circumstance and severity. Patient education and timely intervention is warranted in order to ensure that patient treatment is optimized.

Keywords: Targeted agents; dermatologic toxicities; cancer therapy

Submitted Mar 08, 2019. Accepted for publication Jul 31, 2019.
doi: 10.21037/apm.2019.08.05

Introduction

The landscape of cancer treatment has drastically changed in the last two decades, with molecular targeted therapies becoming ever more prominent as therapeutic options (1). Due in part to the work of Hanahan and Weinberg in categorizing the hallmarks of malignancy and the rise in the use of cancer genomics to guide treatment selection, we are now using more of these targeted therapies than ever before (2,3). Furthermore, we can expect to see increases in the number and breadth of these agents in the future, as we move toward precision medicine in oncology and more therapeutic targets are identified. In 2016, it was estimated that of 631 identified agents in the oncology pharmaceutical pipeline, 47% were targeted small molecules which are given orally (1).

Given that small molecule targeted agents tend to have a cytostatic mechanism of action and exhibit anti-growth and anti-metastatic effects rather than being cytotoxic, they have found widespread use as palliative treatments in advanced disease (4). As a result, clinicians need to be cognizant of the common adverse effects which can occur as a result of the use of these compounds. Traditionally, one of the reasons for pursuing molecular targeted therapy has been the theory that its targeted nature makes it easier
for patients to tolerate compared to traditional cytotoxic chemotherapy. While it may be true that potentially dangerous adverse effects such as myelosuppression are not as common with targeted agents, it has become clear that use of these medications is not without risk and some patients do develop adverse effects that can lead to treatment discontinuation or delay and a significant impact on quality of life (4). This is especially important when we consider that the point of treatment with targeted therapies is often palliation of disease, and that patients with cancer are living longer lives with the incremental improvements we are seeing in efficacy as more and better therapies are introduced. Since quality of life issues should be considered front and centre to this patient group, and in light of the fact that adherence to therapy has the potential to be markedly impacted by toxicity which may in turn negatively affect disease outcomes, it is critical for clinicians to be familiar with the toxicity patterns of targeted agents in order to best inform and empower patients with respect to side effect management and to ensure treatment is optimal.

Although many different molecular targets are currently being exploited therapeutically in cancer treatment, there are a few common threads seen with this approach as far as toxicity is concerned. One very common adverse effect that has been noted with the use of many targeted agents has been dermatologic toxicity, which can present in a myriad of ways (5). One of the first classes of agents to demonstrate skin-related adverse effects was the EGFR inhibitor class, which first came to prominence as a lung cancer therapy in the mid-2000s (6). Patients taking EGFR inhibitors developed a characteristic acneiform rash of varying severity which tended to develop within the first 2 weeks of initiating treatment. In addition, alopecia, eyelash abnormalities, nail and periungual alterations, xerosis, and pruritus were often seen (6). These adverse effects and their management are well described elsewhere in the literature and are a prime example of the way in which modification of cellular signaling pathways can lead to dermatologic toxicities.

Beyond EGFR inhibitors, toxicity to the skin has been reported with various other types of molecular targeted therapies, and is one of the more common adverse effects seen with treatment (7). Our purpose in conducting this review is to outline the specific presentation of dermatologic toxicities in these recently introduced targeted therapies, specifically those with initial FDA approvals between 2013–2018; to outline the significance of these toxicities for patients receiving them for palliation of cancer; and to examine potential management strategies used to ameliorate them.

Methods

In consultation with the authors, a literature search was developed and conducted in December 2018, by a research librarian (CC) in the following databases: PubMed (MEDLINE), Ovid Embase, and Ovid International Pharmaceutical Abstracts. Where applicable, search strategies included a combination of keywords and subject headings, with all keywords restricted to the title and abstract fields only. Broad terms related to cutaneous, dermatologic, and skin toxicities were utilized, as well as specific terminology like rash, hand-foot syndrome, nail disease, and Stevens-Johnson syndrome, among many others. These search terms were combined with terminology for newer, oral cancer drugs, like PARP inhibitors, BRAF/MEK inhibitors, EML4 ALK inhibitors, CDK 4/6 inhibitors, c-MET inhibitors, and BTK inhibitors. All database searches were limited to a date range of 2013–2018. The searches generated a total of 6,771 results, which were imported into EndNote X8 software, where duplicate removal occurred. Additional, more limited searches were conducted after this to examine dermatologic toxicities with copanlisib, idelalisib, and regorafenib, as these were missed in the initial search and it was felt that they should be included in the review. These generated a total of 232 additional results. The complete search strategies can be found in Appendix 1. Medications included in the review were limited to those receiving initial FDA approval between 2013 and 2018, with the exception of BRAF inhibitors used in combination with MEK inhibitors receiving initial FDA approval in this timeframe, crizotinib as a first line ALK inhibitor, and regorafenib.

Dermatologic toxicities of oral targeted therapies

BRAF/MEK inhibitor combinations

The BRAF inhibitors target the mutated V600E BRAF kinase which is responsible for upregulated cellular signaling in various tumour types (44). They were originally licensed for use in advanced melanomas, which often harbour this mutation. Recently, their labeling has expanded to include BRAF V600E mutated non-small cell
Table 1 Small molecule oral anti-cancer agents included in review of dermatologic toxicities

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Agents</th>
<th>FDA approval date (month/year)</th>
<th>Initial dosing</th>
<th>Dermatological adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALK inhibitors (8-12)</td>
<td>Crizotinib</td>
<td>August 2011</td>
<td>250 mg PO BID</td>
<td>Uncommon, and more serious events such as severe skin rash, photodermatitis and toxic epidermal necrolysis are limited to case reports (8-12)</td>
</tr>
<tr>
<td></td>
<td>Ceritinib</td>
<td>April 2014</td>
<td>750 mg PO QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alectinib</td>
<td>December 2015</td>
<td>600 mg PO BID</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brigatinib</td>
<td>April 2017</td>
<td>90 mg PO QD for the first 7 days If well-tolerated for the first 7 days, increase dose to 180 mg PO QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lorlatinib</td>
<td>November 2018</td>
<td>100 mg PO QD</td>
<td></td>
</tr>
<tr>
<td>BRAF/MEK inhibitors (13-18)</td>
<td>Vemurafenib + Cobimetinib</td>
<td>August 2011/V/November 2015 (C)</td>
<td>960 mg PO BID approximately 12 hours apart (Vemurafenib)/60 mg PO QD for 21 days with 7 days off treatment (Cobimetinib)</td>
<td>Photosensitivity, secondary skin malignancies including SCC of the skin and keratoacanthomas, hyperkeratosis, verrucal keratosis, macular and papular rashes, pruritus, erythema nodosum, squamous papilloma, Grover's disease (transient acantholytic dermatosis), xerosis and alopecia (19); Severe dermatologic toxicities when BRAF inhibitors are administered with radiation (20); Addition of MEK inhibitor to BRAF inhibitor reduces incidence of dermatological toxicities (21,22)</td>
</tr>
<tr>
<td></td>
<td>Dabrafenib + Trametinib</td>
<td>May 2015/May 2013</td>
<td>150 mg PO BID (Dabrafenib)/2 mg PO QD (Trametinib)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Encorafenib + Binimetinib</td>
<td>June 2018/June 2018</td>
<td>450 mg PO QD in combination with binimetinib/45 mg PO BID in combination with encorafenib</td>
<td></td>
</tr>
<tr>
<td>BTK inhibitors (23,24)</td>
<td>Ibrutinib</td>
<td>November 2013</td>
<td>MCL/MZL: 560 mg PO QD; CLL/SLL: 420 mg PO QD</td>
<td>Low grade rash (25); Particularly with ibrutinib: non-palpable petechial rash, rash with palpable purpura, maculopapular rash, pityriasis rosea-type rash, brittle nails and textural hair changes (26,27)</td>
</tr>
<tr>
<td></td>
<td>Acalabrutinib</td>
<td>October 2017</td>
<td>100 mg PO BID approximately 12 hours apart</td>
<td></td>
</tr>
<tr>
<td>CDK 4/6 inhibitors (28,29)</td>
<td>Palbociclib</td>
<td>February 2015</td>
<td>125 mg PO QD for 21 days with 7 days off treatment</td>
<td>Alopecia, pruritus, mild rash and Stevens-Johnson syndrome (limited to case reports) (30)</td>
</tr>
<tr>
<td></td>
<td>Ribociclib</td>
<td>March 2017</td>
<td>600 mg PO QD for 21 days with 7 days off treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abemaciclib</td>
<td>September 2017</td>
<td>As monotherapy: 200 mg PO BID with fulvestrant or AI: 150 mg PO BID</td>
<td></td>
</tr>
<tr>
<td>Multikinase inhibitors (31,32)</td>
<td>Regorafenib</td>
<td>September 2012</td>
<td>160 mg PO QD for the first 21 days of each 28-day cycle</td>
<td>Palmar-plantar erythrodynesthesia, rash, alopecia; Particularly with regorafenib: erythema multiforme, Stevens-Johnson Syndrome; Particularly with lenvatinib: hyperkeratosis (33,34)</td>
</tr>
<tr>
<td></td>
<td>Lenvatinib</td>
<td>February 2015</td>
<td>DTC: 24 mg PO QD; RCC: 18 mg PO QD with everolimus 5 mg PO QD; HCC: 12 mg PO QD for patients ≥60 kg or 8 mg for patients &lt;60 kg</td>
<td></td>
</tr>
<tr>
<td>PARP inhibitors (35-40)</td>
<td>Olaparib</td>
<td>December 2014</td>
<td>400 mg PO BID</td>
<td>Severe toxicities are rare; Particularly with niraparib and rucaparib: mild rash (37,38)</td>
</tr>
<tr>
<td></td>
<td>Rucaparib</td>
<td>December 2016</td>
<td>600 mg PO BID</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Niraparib</td>
<td>March 2017</td>
<td>300 mg PO QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Talazoparib</td>
<td>October 2018</td>
<td>1 mg PO QD</td>
<td></td>
</tr>
<tr>
<td>PI3K inhibitors (41,42)</td>
<td>Idelalisib</td>
<td>July 2014</td>
<td>150 mg PO BID</td>
<td>Particularly with idelalisib: maculopapular rash, exfoliative dermatitis, pruritus and erythema (25); particularly with copanlisib: exfoliative rash, pruritus and dermatitis (43)</td>
</tr>
<tr>
<td></td>
<td>Copanlisib</td>
<td>September 2017</td>
<td>60 mg as a 1-hour IV infusion on days 1, 8, 15 of a 28-day cycle on an intermittent schedule (3 weeks on and 1 week off)</td>
<td></td>
</tr>
</tbody>
</table>

PO, orally; BID, twice daily; QD, once daily; SCC, squamous cell carcinoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; AI, aromatase inhibitor; DTC, differentiated thyroid cancer; RCC, renal cell carcinoma; HCC, hepatocellular carcinoma; IV, intravenous.
lungs (NSCLCs), thyroid cancers, and any other malignancy that tests positive for the V600E mutation (13-15). Three agents targeting BRAF are currently available; these include vemurafenib, dabrafenib, and encorafenib. BRAF inhibition has been demonstrated to induce dramatic responses in mutated tumours, however these responses are relatively short-lived and malignant cells eventually develop resistance (45). Overall, BRAF inhibitors are generally well tolerated; however, a number of dermatologic toxicities have been noted which relate to blockade of the BRAF pathway (19). Patients will sometimes develop photosensitivity which can be quite profound. Use of BRAF inhibitors has also been linked to development of secondary skin malignancies, including squamous cell carcinomas (SCC) of the skin and keratoacanthomas. A myriad of other cutaneous adverse effects have been reported, including actinic keratosis, rash, erythema nodosum, squamous papillomas, Grover’s disease (transient acantholytic dermatosis), panniculitis, hand-foot syndrome, and xerosis (19). Additionally, severe dermatologic toxicities have been reported when BRAF inhibitors have been administered concurrently with radiation (20). Alopecia has also been noted with BRAF inhibitors. A meta-analysis conducted by Belum et al. reported that the median incidence of alopecia with vemurafenib was 23.7% (95% CI, 9.6–47.5%) and with dabrafenib was 18.9% (95% CI, 10.5–31.5%) (46).

In 2013, the first MEK inhibitor, trametinib, was licensed for use in combination with BRAF inhibitors in metastatic melanoma (16). MEK inhibitors target mitogen-activated protein kinases which leads to downregulation of MAPK/ERK pathway signaling which is often upregulated in malignancies and act synergistically with BRAF inhibitors, as it has been demonstrated in several melanoma trials that the combination confers superior progression free survival (PFS) and overall survival (OS) over BRAF monotherapy (47). Following the approval of trametinib, two other MEK inhibitors, cobimetinib and binimetinib were also approved (17,18). It has been noted that in addition to improved survival outcomes, addition of a MEK inhibitor to BRAF therapy reduces incidence of various cutaneous toxicities. In a 2013 Australian retrospective cohort study published by Carlos et al., the cohort receiving the combination therapy experienced significantly less verrucal keratosis, cutaneous SCC, and Grover’s disease than the cohort on monotherapy (21). Additionally, a cohort study of 44 patients performed by Sanlorenzo et al. and published in 2014 determined that the development of cutaneous adverse events was reduced (21 events vs. 8, P=0.012) and the time to development was longer for the BRAF/MEK combination vs. BRAF alone, although it should be noted that this was a small retrospective trial with a limited number of patients (22). A set of management strategies for BRAF/MEK combination dermatologic toxicities has been proposed by Welsh and Corrie in a 2015 paper (48). They suggest using soap substitutes and emollients for dry skin, topical steroids and analgesia for erythema nodosum type rash, which may be stepped up to oral corticosteroids (prednisolone 0.5 mg/kg/day or equivalent for 5–7 days) if necessary, and a sunscreen of greater than SPF 30 for prevention of photosensitivity. Macular/Papular rash should be treated according to NCI-CTCAE grading, with grade 1 rashes being observed, grade 2 rashes treated with antihistamines and emollient creams or, if necessary, topical steroids, grade 3 rashes treated as grade 2 but with drug interruption until resolution to grade 1 and consideration of oral corticosteroids as suggested above with erythema nodosum, and grade 4 rashes with discontinuation of therapy and hospitalization if warranted.

Consensus guidelines have been published by the Eastern Cooperative Oncology Group (ECOG) on avoiding severe toxicity seen with the combination of BRAF inhibitors and radiation (20). Almost all grade 3 dermatitis reactions seen in this setting have been during concurrent radiation, and the authors suggest holding BRAF and/or MEK inhibitors for at least 3 days before and after fractionated radiation therapy (RT) and at least 1 day before and after stereotactic radiosurgery (SRS), with time off systemic therapy being minimized as much as possible. Recommendations for RT include considering a dose per fraction of less than 4 Gy unless using a stereotactic approach or the patient has a very poor prognosis or performance status.

**Anaplastic lymphoma kinase (ALK) inhibitors**

ALK inhibitors target the EML4-ALK fusion gene, a mutated gene which occurs in approximately 5% of lung adenocarcinomas, primarily in non-smokers (49). These agents are generally given as monotherapy in metastatic NSCLC in patients who test positive for EML4-ALK (50). The first agent targeting this fusion gene was crizotinib, with second-generation (ceritinib, brigatinib, and alectinib) and third-generation (lorlatinib) agents subsequently introduced to address the problem of developed resistance to ALK inhibition. These drugs tend to have significant efficacy in the ALK positive patients, and indeed crizotinib was initially FDA approved for this population based on
phase I clinical trial data (51). There are some cutaneous toxicities that can result from ALK inhibitor use; however, these are uncommon and more serious events tend to be limited to case reports, including severe skin rash, erythema multiforme, photodermatitis, and toxic epidermal necrolysis cases found in our literature search (52-55). In the PROFILE 1014 phase III study of crizotinib, rash was noted in 11% of participants on the crizotinib arm, with all incidences being either grade 1 or 2 (8). Similarly, some incidence of grade 1 or 2 rash was noted in the alectinib, brigatinib, ceritinib, and lorlatinib phase II and III trials (20%, 18%, 20%, and 14%, respectively) with two reports of grade 3 or higher rash in the brigatinib and ceritinib trials and one report in the lorlatinib trial (9-12). We could not find any specific management strategy for ALK inhibitor-related rash in the literature.

**Cyclin-dependent kinase (CDK) 4/6 inhibitors**

CDK 4/6 inhibitors are agents which target CDKs, a group of enzymes which promote cell division and proliferation and can be upregulated in malignant cells (56). The mechanism of action of these agents involves blockade of the ability of the CDK 4/6 and cyclin D1 protein complex from phosphorylating the retinoblastoma (RB) protein, thus inducing cell cycle arrest at G1. Currently, CDK 4/6 inhibitors are indicated in metastatic breast cancer in hormone-receptor positive (HR+) and HER-2 negative patients and are primarily used in combination with estrogen blockade (28). Three agents are currently on the market; palbociclib, ribociclib, and abemaciclib. Abemaciclib, additionally, is indicated as monotherapy by the FDA after failure of estrogen inhibition and chemotherapy (29). Of the dermatologic adverse events seen with this class of agents, the most noteworthy is alopecia, which was seen in the PALOMA-2 trial comparing the combination of palbociclib and letrozole with letrozole alone, at a rate of 32.9% for grades 1 and 2 compared with 15.8% in the letrozole alone arm (57). High incidences of grade 1 and 2 alopecia were also seen in MONARCH-3 with abemaciclib and in MONALEESA-2 with ribociclib (58,59). There is no specific evidence-based management strategy for prevention or treatment of alopecia with these agents, but patients should be cautioned that they may experience it. As with the ALK inhibitors above, mild rash has been noted in some patients utilizing CDK 4/6 inhibitors. Rash with the use of these agents is rarely severe, though case reports of Stevens-Johnson syndrome have been noted in the literature (30).

**Poly (ADP-Ribose) polymerase (PARP) inhibitors**

PARP inhibitors are agents which inhibit poly (ADP-ribose) polymerase, a group of enzymes involved in cellular DNA repair, and have been shown to be effective in malignancies which harbour a deficiency in repair of DNA damage, including those tumours which are BRCA mutation-associated (60). Inhibition of PARP in these tumours leads to an inability to repair DNA damage because of a defect in the homologous repair pathway which ordinarily would repair double strand DNA breaks, a concept known as synthetic lethality where loss of both the BRCA and PARP pathways leads to cell death. Currently marketed PARP inhibitors include olaparib, rucaparib, niraparib, and talazoparib, and indications for these agents include use in BRCA mutated ovarian and breast cancer (35,36).

Severe dermatologic toxicities with PARP inhibitors are not common; however, similar to the other targeted agents so far covered here, mild rashes related to treatment do occur, particularly with niraparib and rucaparib. Incidence of grade 1 or 2 rash reported in phase III clinical trials in the FDA labeling was 21% with niraparib and 43% with rucaparib (37,38). Approximately 5% of patients experienced a similar rash with olaparib in the OlympiAD trial, and there was no rash reported with talazoparib in the EMBRACA trial in breast cancer patients (39,40). Cases of grade 3 and 4 rash were rare in these trials, with incidences of 1% and 0.5% with niraparib and rucaparib, respectively, and no cases reported with the other agents.

**Phosphoinositide 3-kinase (PI3K) inhibitors**

PI3K inhibitors act to inhibit a group of enzymes which is part of the PI3K/Akt/mammalian target of rapamycin (mTOR) signaling axis which is often upregulated in cancer cells and leads to cell proliferation via the nuclear factor kappa B pathway (61). There are two PI3K inhibitors approved for clinical use today, idelalisib and copanlisib, with several more agents currently undergoing clinical trials. Idelalisib is indicated for use in relapsed or refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic leukemia (SLL), and copanlisib for relapsed FL after two previous failed lines of therapy (41,42).

With idelalisib, a maculopapular rash is sometimes seen, which can be severe in rare cases. Rash of any grade
was noted in 10–22% of patients in clinical trials, but severe (grade 3 or 4) rashes were only seen in 0–2% (52). One case of toxic epidermal necrolysis was noted in combination with rituximab and bendamustine (61). There is no specific management strategy suggested for this rash other than symptomatic treatment and, in severe cases, dose interruption or discontinuation. There is no current literature available on the utility of corticosteroids or antihistamines in this setting (25).

Severe dermatologic toxicities with copanlisib are well documented, and although rare can include maculopapular rash, exfoliative rash, pruritis, and dermatitis (43). The drug’s FDA labeling reports a combined incidence of severe dermatologic toxicities of 3.4% and suggests withholding the drug until resolved if grade 3 toxicity is noted, then reintroducing at a reduced dose from 60 to 45 mg or 45 to 30 mg once resolution occurs (42).

**Bruton’s tyrosine kinase (BTK) inhibitors**

BTK is a protein which is responsible for mediating oncogenic signaling and survival of leukemic cells in several different types of B-cell malignancies. Overactivity of BTK alters cell chemotaxis and facilitates the development of a supportive microenvironment for survival and proliferation of malignant B-cells (62). This has led to development of BTK inhibitors, which induces apoptosis in various B-cell lines. The first agent in this class to be introduced was ibrutinib, with a second agent, acalabrutinib, being subsequently approved (23,24). BTK inhibitors are indicated for use in mantle cell lymphoma (MCL), CLL/SLL, marginal zone lymphoma, and FL.

Ibrutinib related rash occurs relatively frequently, with a 2015 systematic review determining an incidence of 15–28% of all grade rash (63). A wide presentation of rash types has been reported, including non-palpable petechial rashes, rashes with palpable purpura, maculopapular rash, and pityriasis rosea-type rash (25). Rashes are generally grade 1 or 2 and will often spontaneously resolve without the need for treatment, but there have been cases reported of more severe rash for which dose interruption was required. Dose reduction or discontinuation has not been reported. No specific rash management strategy exists in the literature related to ibrutinib. There have also been reports of ibrutinib-induced nail and hair toxicity, which are quite commonly seen. Bitar et al. conducted a prospective study to determine the incidence of hair and nail changes in a cohort of 66 patients receiving ibrutinib therapy for CLL, which found that brittle fingernails were noted in 44 patients (67%) and brittle toenails were seen in 15 patients (23%) (26). These tended to appear several months after starting ibrutinib therapy. It is thought that the pathogenesis of nail changes with ibrutinib is due to disruption of disulfide bonds between cysteine residues, which leads to a breakdown in the integrity of keratin-associated fibrous proteins making up the nail plate (27). Treatment of these changes is not generally considered necessary, although it is recommended that patients keep nails short. Clear nail polish can be used for cosmetic effect, and there is anecdotal evidence that biotin 2.5 mg once daily may be effective, although this needs to be validated. Textural hair changes were also noted in the Bitar study in 17 patients (26%) and were characterized as a softening and straightening, although there have also been reports of increased curliness (26).

Acalabrutinib is a newer agent, and thus there is a paucity of clinical experience with it and little in the literature regarding dermatologic toxicity. Rash has been noted with it in clinical trials, though similar to ibrutinib, this rash was generally low grade (18% grade 1 or 2 rash in the LY-004 trial) and severe rash was rare (0.8%) (24).

**Multikinase inhibitors**

There are many multikinase inhibitors in use in oncology, however most of them did not fall within the specified date range of initial approvals we examined. Lenvatinib, however, is a small-molecule oral inhibitor of the vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1, VEGFR2, VEGFR3). It has also been demonstrated to inhibit other receptor tyrosine kinases related to tumour growth and metastases, including RET, KIT, fibroblast growth factor receptors (FGFR) 1, 2, 3, and 4, and platelet-derived growth factor receptor alpha (PDGFRα) (33). Lenvatinib is indicated clinically for treatment of locally recurrent or metastatic radioactive iodine-refractory differentiated thyroid cancer (DTC), in combination with everolimus for metastatic renal-cell carcinoma, and as a first-line agent for hepatocellular carcinoma (31). There are various cutaneous toxicities that have been seen with lenvatinib, including rash, palmar-plantar erythrodysesthesia (PPE), alopecia, and hyperkeratosis.

PPE, or hand-foot syndrome, is characterized by tender, inflamed, erythematous lesions affecting the palms of the hands and the soles of the feet, and is a specific concern with lenvatinib. Tingling and paresthesias are
often experienced along with the redness and swelling. In the Phase III SELECT study examining lenvatinib use in thyroid cancer, 31.8% of patients experienced PPE, however this was largely grade 1 or 2, with only 3.3% of patients experiencing grade 3 or worse toxicity (34). Thus, lenvatinib dose can generally be continued if PPE occurs, although patients should be cautioned about what to look for and use prophylactic strategies for prevention, including liberal use of moisturizer and avoiding sources of friction or heat on palms or soles. Takahashi et al. published a proposed management strategy for PPE related to lenvatinib which involves continuing at full dose and using moisturizing cream for grade 1 presentation, and interrupting dose and use of betamethasone valerate topically for grade 2 or 3 presentation until resolution to grade 0 or 1 (33). Dose reductions upon resolution are recommended in this strategy in the case of grade 3 presentation or rapid (within 1 week after initiating) appearance of grade 2 PPE. Dosage can be reduced in a stepwise manner from the full dose of 24 to 20, 14, and 10 mg (31).

Rash occurred in the SELECT trial at a rate of 21.4% and was almost entirely grade 1 or 2. Alopecia was seen in 12% of patients and hyperkeratosis in 7% and there was no grade 3 or higher toxicity seen with either adverse effect. There is no specific published management strategy suggested for any of these toxicities, but patients should be made aware that they could happen.

Regorafenib, another multi-kinase inhibitor that inhibits VEGFR1-3, TIE2, KIT, RET, PDGFR, and FGFR, is becoming more commonly used, particularly in colorectal cancer, hepatocellular carcinoma, and gastrointestinal stromal tumours (GIST) (32). As with lenvatinib, several presentations of dermatologic adverse effects can result from regorafenib use. The most common of these is PPE, which was found to occur in 61% of patients overall in a meta-analysis published in 2013, and 20% of PPE was noted to be grade 3 (64). A review of practical advice on regorafenib use published by McLellan et al. in 2015 suggested prophylactic measures such as avoiding heat and constrictive footwear as well as vigorous activities placing stress on the extremities, liberal use of moisturizer, and wearing of thick cotton gloves and socks to protect hands and feet (65). A full skin exam should be conducted prior to initiation of therapy to ensure that changes can be easily detected. Interventions for grade 1 symptoms in this review included use of keratolytics, with 10–40% urea or 5–10% salicylic acid being suggested, as well as topical analgesics such as lidocaine gel and skin cooling packs for pain. Clobetasol 0.05% ointment can be added for erythema if grade 2 symptoms develop, and topical antibiotics or antiseptics for desquamation in the case of grade 3 symptoms. Dose reduction from the standard 160 mg daily 21 days out of 28 was suggested at grade 2, and interruption of treatment for at least 7 days until resolution of toxicity at grade 3 (or unresolved grade 2), followed by reintroduction at reduced dosage levels of 120 and 80 mg daily. In patients developing hyperkeratotic lesions, tazarotene 0.1% topically as an antiproliferative agent may be helpful. Interestingly, a Japanese group published a retrospective study in 2018 suggesting that PPE severity may be associated with improved efficacy in metastatic colorectal cancer (66).

Maculopapular rash can also occur with regorafenib treatment with an incidence of 18–26% in the literature, although most rashes are grade 1 or 2 (67,68). Preventative measures are again suggested, including alcohol-free emollients, mild soaps, and avoiding direct sun exposure, and all grades of rash can be effectively managed with antihistamines and a short course of clobetasol propionate 0.05% in cold cream (69). Severe, generalized toxicities such as Stevens-Johnson syndrome are rare, but there have been case reports published in the literature (70,71).

Discussion

Clearly, when dealing with oral molecular targeted agents there is a wide range of potential dermatologic adverse events that may occur, ranging from mild grade 1 rash to severe and potentially life threatening conditions such as toxic epidermal necrolysis. Vigilance by the patient, therefore, is extremely important, as they will be the first to notice if something is amiss. Educating the patient on what to look for and expect in terms of skin toxicity with a given targeted agent should be part of the teaching process upon initiation of treatment. Prophylactic strategies such as frequent moisturizing, use of mild cleansers, and avoidance of skin irritants are appropriate and depending on the circumstance and drug used may help prevent problems from occurring.

Adherence to therapy is extremely important to optimize outcomes in palliative cancer therapy. There is generally a lack of published evidence on the subject of adherence to TKIs in areas other than BCR-ABL inhibitor therapy in chronic myelogenous leukemia (CML). The CML population demonstrates that, in addition to a clear link between outcomes and degree of adherence to therapy, toxicity had a direct impact on adherence in multiple assessments, with 17.6%
of patients in one survey admitting to skipping doses directly due to side effects (72). A 2015 study by Zuo et al. on dermatologic toxicity with cabozantinib, which causes PPE, hair pigmentation, xerosis, scrotal erythema and ulceration, and nail splinter hemorrhages, concluded that early detection and prompt treatment of toxicities may improve adherence to therapy (73). Thus, it is very important for us as clinicians to teach and empower patients to prophylactically manage toxicities and report them promptly, and intervene on an expedient basis when necessary. Rash in particular is an adverse effect which is likely under-recognized and undertreated, and a discussion with the patient should be had around how a rash may impact quality of life and how rashes may be managed appropriately. Quality of life in and of itself should be considered one of the primary goals of therapy in palliative cancer treatment, and data exists in the population of patients using EGFR inhibitors regarding impact of dermatologic toxicities on quality of life that can likely be extrapolated to the new TKIs. Yang et al. published a prospective study of 344 EGFR mutation-positive lung cancer patients utilizing EuroQol five-dimension and World Health Organization Quality-of-Life—brief questionnaires in order to determine scores for patients taking erlotinib, gefitinib, and afatinib (74). They determined that quality of life scores appeared to be worse in patients taking afatinib, and that one of the determinants of this was impact of treatment on body image, with dermatologic toxicities such as increased rates of paronychia and folliculitis contributing to this. Thus, clinicians need to be cognizant of the fact that dermatologic manifestations seen with these agents can be burdensome for patients and that they should be treated seriously.

Conclusions
Dermatologic toxicities are not uncommon with new targeted agents, with secondary cutaneous malignancies being seen with BRAF inhibitors, alopecia with CDK 4/6 inhibitors, hair and nail toxicity with ibrutinib, and hand-foot syndrome seen with lenvatinib, in addition to other, more rare toxicities. Low grade rash is very common and tends to be seen across targeted therapies. In order to properly empower the patient and manage treatment optimally, it is important to ensure that patients are well informed of the possibility and presentation of these toxicities, how to prophylactically manage them, and when to report to a health care provider. Prescribers should be aware of the management strategies that exist to treat these toxicities and intervene on an expedient basis when necessary to improve treatment outcomes and preserve patient quality of life in the palliative setting.

Acknowledgments
Funding: None.

Footnote
Provenance and Peer Review: This article was commissioned by the Guest Editors (Jan Gaertner, Charles B. Simone II and Fiona Lim) for the series “Clinical Challenges and Pitfalls in Early Palliative Care: Practical Knowledge and Guidance from other Medical Specialties” published in Annals of Palliative Medicine. The article was sent for external peer review organized by the Guest Editors and the editorial office.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/apm.2019.08.05). The series “Clinical Challenges and Pitfalls in Early Palliative Care: Practical Knowledge and Guidance from other Medical Specialties” was commissioned by the editorial office without any funding or sponsorship. Dr. McFarlane has received honoraria as a consultant from AstraZeneca to this section. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References
1. Global Oncology Trends 2017. Available online:


29. VERZENIO™ [Package Insert]. Indianapolis, IN: Lilly USA, LLC, 2018.


34. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib


Search strategies: PubMed (MEDLINE)


Filters activated: publication date from 2013/01/01 to 2018/12/31.

Ovid embase

1. exp skin disease/
2. exp skin manifestation/
3. exp skin toxicity/
4. exp skin injury/
5. exp drug eruption/
6. exp skin defect/
7. exp rash/
8. exp hyperpigmentation/
9. exp melanosis/
10. exp hand foot syndrome/
11. exp hypersensitivity/
12. exp allergic reaction/
13. exp nail disease/
14. exp nail dystrophy/
15. exp petechia/
16. exp purpura/
17. exp photosensitivity/
18. exp photodermatosis/
19. exp pruritus/
20. exp urticaria/
21. exp stomatitis/
22. exp erythema multiforme/
23. exp dry skin/
24. exp skin lupus erythematosus/
25. exp dermatitis/
26. exp erythema/
27. exp Stevens Johnson syndrome/
28. (cutaneous reaction* or cutaneous toxicit* or cutaneous complication* or cutaneous drug eruption* or cutaneous adverse
effect* or cutaneous adverse event* or cutaneous side effect* or cutaneous effect* or cutaneous disease* or cutaneous
manifestation* or cutaneous injur* or cutaneous abnormalit* or dermatologic reaction* or dermatologic toxicit* or
dermatologic complication* or dermatologic drug eruption* or dermatologic adverse effect* or dermatologic adverse
event* or dermatologic side effect* or dermatologic effect* or dermatologic disease* or dermatologic manifestation* or
dermatologic injur* or dermatologic abnormalit* or skin reaction* or skin toxicit* or skin complication* or skin injur*
or skin side effect* or skin manifestation* or skin abnormalit* or skin damage or rash* or exantheme or hyperpigmentation
or hypermelanos* or hand-foot syndrome or palmar-plantar erythrodysesthesia or palmoplantar erythrodysesthesia or
hypersensitivit* or allergic reaction* or mucocutaneous or nail dystroph* or nail disease* or nail disorder* or nail
toxicit* or nail change* or petechiae or purpura or photosensit* or photodermatitis or pruritus or urticaria or stomatit*
or erythema multiforme or dry skin or cutaneous lupus erythematosus or dermatitis or dermatos* or erythema or
stevens-johnson syndrome).ti,ab.
29. or/1-28
30. exp nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor/
31. exp talazoparib/
32. exp olaparib/
33. exp rucaparib/
34. exp niraparib/
35. exp encorafenib/
36. exp binimetinib/
37. exp vemurafenib/
38. exp cobimetinib/
39. exp dabrafenib/
40. exp trametinib/
41. exp alectinib/
42. exp ceritinib/
43. exp crizotinib/
44. exp brigatinib/
45. exp abemaciclib/
46. exp palbociclib/
47. exp ribociclib/
48. exp cabozantinib/
49. exp Bruton tyrosine kinase inhibitor/
50. exp ibrutinib/
51. (PARP inhibitor* or polyadenosine ribose polymerase inhibitor* or poly ADP ribose polymerase inhibitor* or poly ADP-riboseylation inhibitor* or talazoparib or Tälzenna or olaparib or Lynparza or rucaparib or Rubraca or niraparib or Zejula or BRAF MEK inhibitor* or encorafenib or Braftovi or binimetinib or Mektovi or vemurafenib or Zelboraf or cobimetinib or Cotellic or dabrafenib or Tafinlar or trametinib or Mekinist).ti,ab.
52. (EML4 ALK inhibitor* or alectinib or Alecensa or ceritinib or Zykdia or crizotinib or Xalkori or brigatinib or Alunbrig or CDK 4 6 inhibitor* or cyclin-dependent kinase 4 6 inhibitor* or abemaciclib or Verzenio or palbociclib or Ibrance or ribociclib or Kisqali or c-MET inhibitor* or cabozantinib or Cometriq).ti,ab.
53. (BTK inhibitor* or Bruton tyrosine kinase inhibitor* or Brutons tyrosine kinase inhibitor* or ibrutinib or Imbruvica).ti,ab.
54. or/30-53
55. 29 and 54
56. limit 55 to yr="2013 -Current"

Additional search strategies: idelalisib/copanlisib

The following search terms were entered into PubMed(MEDLINE): ("idelalisib"[Supplementary Concept] OR "idelalisib"[All Fields]) OR ("2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide"[Supplementary Concept] OR "2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide"[All Fields] OR "copanlisib"[All Fields]) OR ("idelalisib"[Supplementary Concept] OR "idelalisib"[All Fields] OR "zydelig"[All Fields]) OR Aliqopa[All Fields])
Seventy-two results were obtained, of which 4 were eventually used in the review.

**Regorafenib**

The following search terms were entered into PubMed(MEDLINE): (("regorafenib"[Supplementary Concept] OR "regorafenib"[All Fields]) OR "Stivarga"[All Fields]) AND (("skin"[MeSH Terms] OR "skin"[All Fields]) AND ("toxicity"[Subheading] OR "toxicity"[All Fields])) OR (cutaneous[All Fields] AND ("toxicity"[Subheading] OR "toxicity"[All Fields])) OR (cutaneous[All Fields] AND manifestations[All Fields]) OR ("hand-foot syndrome"[MeSH Terms] OR ("hand-foot"[All Fields] AND "syndrome"[All Fields]) OR "hand-foot syndrome"[All Fields]) OR ("palmar"[All Fields] AND "plantar"[All Fields] AND "erythrodysesthesia"[All Fields]) OR "palmar plantar erythrodysesthesia"[All Fields]) OR ("stevens-johnson syndrome"[MeSH Terms] OR ("stevens-johnson"[All Fields] AND "syndrome"[All Fields]) OR ("stevens"[All Fields] AND "johnson"[All Fields] AND "syndrome"[All Fields]) OR "stevens johnson syndrome"[All Fields]) OR ("toxic"[All Fields] AND "epidermal"[All Fields] AND "necrolysis"[All Fields]) OR "toxic epidermal necrolysis"[All Fields]) OR ("toxicity"[Subheading] OR "toxicity"[All Fields])

One hundred sixty results were obtained, of which were eventually used in the review.